BioLargo

US: BLGO

$22.5m market cap

$0.17 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo made progress on multiple fronts during Q3 and subsequently toward becoming a fully fledged, diversified technology company. First, it announced that Clyra had received feedback from the FDA regarding the data necessary to complete the 510(k) application process, which should be finished in the next six months. Second, the company broke revenue records in October with BioLargo Engineering, Science & Technologies (BLEST) having its first break-even month. Finally, progress continues toward the 2019 launch of the AOS with the independent validation of the system’s capacity to eliminate micropollutants.

Sector
Healthcare
Share price graph
Price performance
%
1m
3m
12m
Actual (21.8) (29.0) (31.7)
Relative* (23.3) (37.2) (34.6)
52-week high/low US$0.4/US$0.2
*% relative to local index
Key management
Dennis Calvert President & CEO